

**RESOLUTIONS
OF
TISSUE REGENIX GROUP PLC
(Company number 05969271)
(the "Company")**

SATURDAY



A992K40J

A10

11/07/2020

#139

COMPANIES HOUSE

AT AN ANNUAL GENERAL MEETING of the Company duly convened and held at the offices of Squire Patton Boggs (UK) LLP, Squire Patton Boggs (UK) LLP at 6 Wellington Place, Leeds LS1 4AP at 10:00 a.m. on 30 June 2020, the following resolutions were passed as an ordinary resolution and special resolutions as indicated below.

ORDINARY RESOLUTIONS

1. That, pursuant to section 551 of the Companies Act 2006 ("**Act**"), the directors be generally and unconditionally authorised to allot Relevant Securities (as defined below):
 - 1.1 up to an aggregate nominal amount of £2,339,999; or
 - 1.2 comprising equity securities (as defined in section 560(1) of the Act) up to a further aggregate nominal amount of £2,339,999 in connection with an offer by way of a rights issue:
 - 1.2.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of ordinary shares held by them; and
 - 1.2.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange, provided that these authorities shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution or on 30 September 2021 (whichever is the earlier), save that, in each case, the Company may make an offer or agreement before the authority expires which would or might require Relevant Securities to be allotted after the authority expires and the directors may allot Relevant Securities pursuant to any such offer or agreement as if the authority had not expired.

In this resolution 1, "**Relevant Securities**" means shares in the Company or rights to subscribe for or to convert any security into shares in the Company; a reference to the allotment of Relevant Securities includes the grant of such a right; and a reference to the nominal amount of a Relevant Security which is a right to subscribe for or to convert any security into shares in the Company is to the nominal amount of the shares which may be allotted pursuant to that right.

These authorities are in substitution for all existing authorities under section 551 of the Act (which, to the extent unused at the date of this resolution, are revoked with immediate effect).

SPECIAL RESOLUTIONS

2. That, subject to the passing of resolution 1 and pursuant to section 570 of the Act, the directors be and are generally empowered to allot equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authority granted by resolution 1 as if section 561(1) of the Act did not apply to any such allotment, provided that this power shall be limited to the allotment of equity securities:

- 2.1 in connection with an offer of equity securities (whether by way of a rights issue, open offer or otherwise):

2.1.1 to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of ordinary shares held by them; and

2.1.2 to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange; and

- 2.2 otherwise than pursuant to paragraph 2.1 of this resolution, up to an aggregate nominal value nominal amount of £701,999,

and this power shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution or on 30 September 2021 (whichever is the earlier), save that the Company may make an offer or agreement before this power expires which would or might require equity securities to be allotted for cash after this power expires and the directors may allot equity securities for cash pursuant to any such offer or agreement as if this power had not expired.

This power is in substitution for all existing powers under section 570 of the Act (which, to the extent unused at the date of this resolution, are revoked with immediate effect).


3. That, pursuant to section 701 of the Act, the Company be and is generally and unconditionally authorised to make market purchases (within the meaning of section 693(4) of the Act) of ordinary shares in the capital of the Company ("**Shares**"), provided that:

3.1.1 the maximum aggregate number of Shares which may be purchased is 701,999,753; and

3.1.2 the minimum price (excluding expenses) which may be paid for a Share is 0.1p; and

3.1.3 the maximum price (excluding expenses) which may be paid for a Share is an amount equal to 105 per cent of the average of the middle market quotations for a Share as derived from the Daily Official List of the London Stock Exchange plc for the five business days immediately preceding the day on which the purchase is made;

and (unless previously revoked, varied or renewed) this authority shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution or on 30 September 2021 (whichever is the earlier), save that the Company may enter into a contract to purchase Shares before this authority expires under which such purchase will or may be completed or executed wholly or partly after this authority expires and may make a purchase of Shares pursuant to any such contract as if this authority had not expired.



.....
Gareth Jones (Director)

For and on behalf of Tissue Regenix Group plc